About Us

Pharmaceuticals

Research & Development

Tokyo New Drug Research Laboratories and Fuji Laboratory are the core centers for our research and development activities in Japan.

At the Tokyo New Drug Research Laboratories we conduct extensive research activities, including searching for new materials and product opportunities and their biological screening, molecular design, and preclinical studies such as biokinetic studies of medicine.

The Fuji Laboratory has two research divisions: 1) safety research and drug formulation research, where researchers are dedicated to product safety testing, and 2) research on drug delivery systems (DDS) for efficiently delivering drugs to the target site, development of new dosage forms, development of over-the-counter (OTC) drugs, and production of investigational agents.

We are working on research and development of our global products mainly in the United States, Europe and Asia.

Target Areas of R&D
Lifestyle -related diseases
Dyslipidemia
Type 2 Diabetes
Arteriosclerotic disease
Immunity Inflammation
Cancer
Inflammatory disease
Skin disease
Sensory organ diseases
Eye disease
Equilibrium and auditory function disorders
Pipeline

Last Updated : October 2017.

Lifestyle -related diseases
Dyslipidemia
Development Code /
Generic Name
Country / Region Stage Indications Category
NK-104-PH / Pitavastatin EU Filed Familial Hypercholesterolemia
(Pediatrics)
HMG-CoA reductase inhibitor
K-877 / Pemafibrate Japan Approved HyperlipidemiaSelective PPARα Modulator
US PIII Dyslipidemia
EU PIII
K-877-FL / Pemafibrate Japan PII Non-alcoholic fatty liver/
Non-alcoholic steatohepatitis
Selective PPARα Modulator
K-877-BC / Pemafibrate Japan PI Primary biliary cholangitis Selective PPARα Modulator
CSG452 / Tofogliflozin US PII Type 2 Diabetes Mellitus SGLT2 inhibitor
EU PII
SK-0403 / Anagliptin US PII Type 2 Diabetes Mellitus DPP-4 inhibitor
EU PII
K-118 / Arhalofenate US PII Gout
Hyperuricemia
URAT1 inhibitor
K-312 US PI Dyslipidemia
Immunity inflammation
Development Code /
Generic Name
Country / Region Stage Indications Category
NIK-333, K-333 /
Peretinoin
Japan PIII Prevention of Recurrence of
Liver Cancer
Apoptosis inducer
ASIA PIII
EU PI
Sensory organ diseases
Development Code /
Generic Name
Country / Region Stage Indications Category
K-115-R / Ripasudil
hydrochloride hydrate
Japan PII Diabetic Retinopathy Rho kinase inhibitor
Other
Development Code /
Generic Name
Country / Region Stage Indications Category
K-828-SP /
Sodium Valproate
Japan PIII Spinal Muscular Atrophy
K-163-SZ / Pyridoxamine Japan PII Schizophrenia
K-134 Preparing Under consideration PDE3 inhibitor